UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): ___ Form 10-K ___ Form 20-F ___ Form 11-K
_XX_ Form 10Q ___ Form N-SAR
For Period Ended: March 31, 2000
( ) Transition Report on Form 10-K
( ) Transition Report on Form 20-F
( ) Transition Report on Form 11-K
( ) Transition Report on Form 10-Q
( ) Transition Report on Form N-SAR
For the Transition Period Ended:
- ------------------------------------------------------------------
Read Instructions (on back page) Before Preparing Form. Please
Print or Type.
- ------------------------------------------------------------------
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
__________________________________________________________________
PART I - REGISTRANT INFORMATION
__________________________________________________________________
Full Name of Registrant
Nyer Medical Group, Inc.
- ------------------------------------------------------------------
Former Name if Applicable
N/A
_________________________________________________________________
Address of Principal Executive Office (Street and Number)
1292 Hammond Street
_________________________________________________________________
City, State, and Zip Code
Bangor, Maine 04401
Part II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
(a) The reasons described in reasonable detail in Part III
| of this form could not be eliminated without
| unreasonable effort or expense;
|
| (b) The subject annual report, semi-annual report,
| transition report on Form 10-K, Form 20-F, 11-K, Form
XX | N-SAR, or portion thereof, will be filed on or before
| the fifteenth calendar day following the prescribed
| due date; or the subject quarterly report of
| transition report on Form 10-Q, or portion thereof
| will be filed on or before the fifth calendar day
| following the prescribed due date; and
|
| (c) The accountant's statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K,
10-Q, N-SAR, or the transition report or portion thereof, could
not be filed within the prescribed time period. Attach Extra
Sheets if Needed)
For matters unrelated to the financial position or performance of
Nyer Medical Group, Inc., the Company requires additional time to
prepare the Company's 10-Q so the financial statements are
presented accurately.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification.
Karen L. Wright (207) 942-5273
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30
of the Investment Company Act of 1940 during the preceding
12 months (or for such shorter) period that the registrant
was required to file such reports been filed? If answer
is no, identify report(s). XX Yes No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last
fiscal year will be reflected by the earnings statements to
be included in the subject report or portion thereof?
Yes XX No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state
the reasons why a reasonable estimate of the results cannot
be made.
Nyer Medical Group,Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 15, 2000 By /s/ Karen L. Wright, Treasurer
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duty authorized representative. The
name and title of the person signing the form shall be typed or
printed beneath the signature. If the statement is signed on
behalf of he registrant by an authorized representative (other than
an executive officer), evidence of the representative's authority
to sign on behalf of the registrant shall be filed with the form.
